Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Medicines Company Net Income Rises, But Shares Fall

By Pharmaceutical Processing | July 24, 2013

The Medicines Co. said Wednesday its net income grew 32 percent in the second quarter as sales of its drugs increased and research costs fell.

Its profit came in shy of Wall Street’s forecasts and its shares slumped $1.58, or 5.1 percent, to close at $29.73.

The company said U.S. sales of its anti-clotting drug Angiomax grew 14 percent to $137.9 million. International sales also improved, and the company reported $17.9 million in U.S. sales of Recothrom, an anti-bleeding drug it licensed from Bristol-Myers Squibb Co. in December.

The company said its net income grew to $18.1 million, or 30 cents per share, from $13.8 million, or 25 cents per share. Revenue rose 27 percent, to $172.8 million from $135.7 million

Analysts were expecting net income of 32 cents per share and $168.9 million in revenue, according to FactSet.

Medicine Co.’s research and development costs declined after it finished testing its anti-clotting drug. The Food and Drug Administration is reviewing its application for marketing approval, and the company expects a decision in the second quarter of 2014.

The company maintained its revenue guidance, saying sales will grow 20 to 22 percent for the year. That implies a total of $670.3 million to $681.5 million, and analysts expect $686.7 million on average.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE